BillionToOne

BillionToOne IPO: Molecular diagnostics company debuts on the Nasdaq

Novo Nordisk A/S

Eli Lilly and Company

Competition with Eli Lilly and abrupt changes in Novo Nordisk's management are putting pressure on its performance

Ozempic's creator lowered forecasts for the fourth time this year. Should we sell the stock?

Pfizer Inc.

Novo Nordisk, the maker of obesity drugs Wegovy and Ozempic, and US pharma company Pfizer have improved their offers to buy US startup Metsera, which develops weight-loss drugs. The company itself still considers Novo's offer "more favorable" despite the escalating battle for the deal, the Financial Times <a href="https://www.ft.com/content/ab202cb5-ee27-4257-b2ee-431408c970c1">writes</a>.

Novo Nordisk and Pfizer raise stakes in battle for weight loss drug developer

Pharma companies squabble over a promising startup in the market for weight management products

Pfizer sues Novo Nordisk and Metsera - Oninvest

Danish Novo Nordisk will release its quarterly report on Nov. 5.

Novo Nordisk's 5 challenges: what's at the center of investment banks' attention 

Novo Nordisk has entered into a battle with Pfizer over Metsera. Why do they want this biotech startup?

HSBC Holdings plc

Novartis AG

Japan's Nikkei index crossed the 50,000-point mark for the first time amid optimism in anticipation of U.S.-China talks and a rebound on Wall Street. Novartis buys biotech Avidity Biosciences for $12 billion, strengthening its position in RNAi therapeutics. HSBC pledges $1.1 billion in reserves after a failed Madoff judgment in Luxembourg. These and other topics - in our review of key events by the morning of October 27.

Highlights for the morning: Nikkei record, Novartis deal and the new role of bitcoin miners

Abbott Laboratories

Air Products and Chemicals, Inc.

Johnson & Johnson

Generac Holdings Inc.

ITT Inc.

Marex Group plc

Amazon.com, Inc.

GitLab Inc.

NVR, Inc.

Barrick Mining Corporation

Anglo American plc

Sibanye Stillwater Limited

AI is a risky strategy, real production is a conservative one: Oninvest asked Astero Falcon portfolio manager Alena Nikolaeva where to invest $10,000 if the horizon is about a year and the goal is to increase capital. Two strategies include companies from the "old" economy.

Where to invest $10,000 right now: the renaissance of real manufacturing 

AstraZeneca PLC

Daiichi Sankyo Company, Limited

The Enhertu drug was found to be more effective than a drug from Swiss Roche

AstraZeneca's drug has produced positive results in the fight against breast cancer. What about the stock?

The retail price of Ozempic, which Trump has called a "weight-loss drug," is about $1,000 for a one-month course

Trump has promised to cut the price of Ozempic to $150. Novo Nordisk and Eli Lilly shares fell

Akero Therapeutics, Inc.


The maker of Ozempic and Wegovy makes its first major deal under new CEO Mike Doustdar

Liver drugmaker Akero to be acquired by Novo Nordisk; shares soar 17%

The share price appreciation is giving Wall Street confidence that after a prolonged "winter" in biotech is finally beginning to thaw

Pharmaceutical Companies